Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I tend to agree because it is not an available sanction for the original offence which is why we are here in the first place. Entire thing is a vicious circle. The reason i said it is that it seems that they are looking for another solution maybe one that can be mutually agreed and thus setting a precedence for future OIP's.
It wasn't actually the same situation. They didn't receive an OIP or get halted. They just had filed incorrectly as I can recollect. So not the same as this here. But yes $50K has been handed down to a few tickers but under different circumstances than this.
Ya Just think they want to justify a fine $50K is my guess but that fine was not in the original choices that were available.
Yup I realize that is the case we all do. NY offices for them are virtual just pointing out the filing and what it was for. These guys operate overseas.
$DBMM SOS Change Filed Today New Business Address
845 Third Avenue
6th Floor
NEW YORK, NY 10022
http://search.sunbiz.org/Inquiry/CorporationSearch/SearchResults?InquiryType=EntityName&InquiryDirectionType=ForwardRecord&SearchTerm=Digital%20Brand%20Media%20%26%20Marketing%20Group%2C%20Inc&SearchNameOrder=DIGITALBRANDARCHITECTS%20L200002094820&ListNameOrder=DIGITALBRANDMEDIAMARKETINGGROU%20P980000841031&Detail=FL.DOS.Corporations.Shared.Contracts.FilingRecord
$INCC keep up the fight Max thx for the alert. Great Chart Man right here folks best in the business great read on this ticker.
TN 2016 long time!!! I am in here just don't focus on this platform much any more. Good prices for sure tucked away for later. $INCC
As Soon as the manipulation stops it will get there in a hurry.
$IPSI on the simmer this has to noil over soon. There is just to much that is good on this Ticker. NASDAQ level Execs and Advisory.
Read the filing a few times looks to me that this is the way the SEC Commission introduces a fine which was not an option before. $50K would be my guess and lets put this to bed.
$DBMM
Filed for Reinstatement and Registered Agent Last night AH.
https://esos.nv.gov/EntitySearch/BusinessFilingHistory?businessid=188230
$IPSI Added the DD is great and SS to match. This will be very good in time.
Innovation Pharmaceuticals’ Brilacidin for the Treatment of COVID-19 Receives FDA Fast Track Designation
Phase 2 clinical trial of Brilacidin for COVID-19 anticipated to commence this month
January 14, 2021 07:30 ET | Source: Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce that the U.S. Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of Brilacidin as a potential treatment for COVID-19. Brilacidin is a first-in-class Host Defense Protein (HDP) mimetic with antiviral, anti-inflammatory and antibacterial properties.
Fast Track designation facilitates the development and expedites the review of drugs that are intended to treat serious and life-threatening conditions and show the potential to fill an unmet medical need. Drugs developed under the Fast Track program are afforded increased access to FDA staff and may qualify for other programs to further expedite their clinical development, such as priority review and accelerated approval.
“Receiving Fast Track designation is an important acknowledgment of the results of our COVID-19 laboratory research,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “Fast Track designation is well-timed, as we anticipate starting our Phase 2 clinical trial in hospitalized COVID-19 patients this month, and should help bring Brilacidin to patients faster in these dire times.”
To date, Brilacidin has received Fast Track designation for three different clinical indications: COVID-19, Oral Mucositis, and Acute Bacterial Skin and Skin Structure Infection (qualifying for Fast Track under Qualified Infectious Disease Product designation).
Brilacidin and COVID-19
Brilacidin is one of the few drugs targeting COVID-19 that has been tested in human trials (a total of 8) for other clinical indications, providing established safety and efficacy data on over 460 subjects, thereby potentially enabling it to rapidly help address the novel coronavirus crisis. Laboratory testing at independent laboratories supports Brilacidin’s antiviral ability to safely and potently inhibit SARS-CoV-2, and multiple strains of human coronaviruses (H-CoVs). In a human lung cell line against SARS-CoV-2, Brilacidin achieved a Selectivity Index of 426. A molecular screening study of 11,552 compounds also supports Brilacidin as a promising novel coronavirus treatment. Brilacidin antiviral research to date has been limited to laboratory-based experiments. Additional pre-clinical and clinical data support Brilacidin’s inhibition of IL-6, IL-1ß, TNF-a and other pro-inflammatory cytokines and chemokines, which have been identified as central drivers in the worsening prognoses of hospitalized COVID-19 patients. Brilacidin’s robust antimicrobial properties might also help to fight secondary bacterial infections, which can co-present in up to 20 percent of COVID-19 patients. Collectively, these data support Brilacidin as a unique 3 in 1 combination—antiviral, immuno/anti-inflammatory, and antimicrobial—COVID-19 therapeutic candidate, with pan-coronavirus treatment potential. A preprint supporting Brilacidin’s COVID-19 treatment potential can be downloaded at the link below.
Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2
https://www.biorxiv.org/content/10.1101/2020.10.29.352450v1.full
Wow Great news this AM.
$BLPG Big DD.....What up Hookie been a while.
So now also ties Hypur and "Caliva" who is partnered with Monogram Cannabis Jay-z's company.
https://www.usatoday.com/story/money/2020/12/10/jay-z-launches-monogram-cannabis-product-line/3884678001/
$BLPG and then there is this! "Shawn Carter (Jay-Z) on Thursday launched Monogram, a premium cannabis brand in partnership with California-based company, Caliva." Full Article from Dec 2020. 👇👀https://t.co/OyqWAR9KEa https://t.co/UXcXkG7pvg
— RRR1 (@rrr1sr) January 5, 2021
$BLPG not just any Mob!! GLTY as well.
LOL $BLPG trust the DD always and need to understand what you are seeing. Getting current for a reason.
$BLPG good people in control; and Great Traders finding this ticker.
Solid DD Dropping here.
$BLPG So many connections, let's see how this one pans out !! pic.twitter.com/7LRAAK58IY
— Percy Holton Jr (@empowered_succ) January 4, 2021
$ICNM damn. Who would have though those shares could have been sold last week for T-1 sucks but no way you could have known what was coming Volume wise.
Real moves don't happen in Trips these don't really thin out until Dubs so ya some MOMO is needed here. Would be good to find out who is really behing this no one drops 180K on a dead horse to break even ot 1 tick flip it much better dead plays with SS that can move out there has to be a reason for this particular one to get that load up. Sorry for the guy who dumped 100M a few months back Tax W/O #'s market sold under 0001 got filled at 00005. Didn't even know someone could do that until he did it thought one had to go through broker for that.
If it is a Custo I would not be excited to see David Lazzar. Would prefer a David Cutler or Benjamin Berry with Synergy. But history has shown they don't often play with NVSOS tickers they are more DE SOS.
Time will tell here.
FYI BB and his followers were not responsible for the initial 180K volume on Tuesday that is still a mystery. I know this for a fact. Not him. But he is in for a lotto here. I wouldn't be surprised if this is a sold ticker as we speak or like someone just mentioned a Custo gaining control with share size before filing the Petition in Clack County Courts.
BB is definitely a big whale in OTC I have it on good sourcing that the mother of all whales is bid sitting Since late Wednesday and as of now hasn't been filled.
Big man coming in one that takes big size on a lotto when he comes in if T-2's start to run on Monday it wouldn't shock me if he slaps.
Anyone who wishes to question my sources. Don't!! Those who know me know I don't play games. (Hint we had a DM talk about this ticker and he is coming) Ask the afore mentioned whale BB he will vouch for me.
They loaded 2B ones already now they need to take out 2's wait for it!!!! This is how a No Bid becomes relevant again.
No makes no sense to spend 180K on a stock just for a tick or 2 something will be put out which will spark this.
Got to be I had more than enough opportunity to bid dump today but after years of being stuck makes no sense not to see what they have in store. Hoping for the bomb to drop soon. No other explanation.
Don't matter 1B bought up in minutes. No one does that unless they are thinking much more than a break even. Or 1 tick flip. Makes no sense something big has to come to cause a significant increase in PPS. Past doesn't matter now that kind of money in not spent for nothing.
Glad for you and yes Merry X-mas too you and yours. Bro
Good for you I have held this long and someone or a group didn't start buying 1's for even i will hang or get hung LOL
That has got to be the fasted 3/4B shares bought I have ever seen. $ICNM
I think so. Continuous small accumulation so not to trigger scanners. Then the pump is on. Works for me.
FDA Grants IND Approval for Phase 2 Clinical Trial of Innovation Pharmaceuticals’ Brilacidin for Treating COVID-19
December 21, 2020 07:00 ET | Source: Innovation Pharmaceuticals Inc.
Brilacidin’s potent in vitro inhibition of the Washington and Italian strains of SARS-CoV-2 support its potential to inhibit emerging coronavirus mutations (variants), such as those in the United Kingdom, Denmark and South Africa
120-patient trial to be conducted at U.S. and international clinical sites
Primary endpoint time to sustained recovery through Day 29
WAKEFIELD, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company developing Brilacidin, a Host Defense Protein (HDP) mimetic representing a new class of drug with antiviral, anti-inflammatory and anti-bacterial properties, is pleased to announce that the U.S. Food and Drug Administrations (FDA) has approved the Company’s Investigational New Drug (IND) application to proceed with initiation of a Phase 2 clinical trial of Brilacidin in hospitalized patients with COVID-19.
Brilacidin has been shown in vitro to be effective against different SARS-CoV-2 strains (Washington and Italian), as well as multiple human coronaviruses, making it less likely to be affected by emerging mutations (in the United Kingdom, Denmark and South Africa) and further differentiating the drug from other COVID-19 treatments in development today.
With its unique HDP mimetic properties, Brilacidin has potential to exert antiviral activity across SARS-CoV-2 variants. The sudden emergence of highly contagious new variants of the coronavirus illuminates the urgent need for drugs, like Brilacidin, with a different mechanism of action from current antivirals to get this resilient virus under control.
The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled, multi-national, multi-center study expected to enroll approximately 120 patients with moderate-to-severe COVID-19. The trial’s primary endpoint is time to sustained recovery through Day 29 based on the National Institute of Allergy and Infectious Diseases (NIAID) Adaptive COVID-19 Treatment Trial (ACTT) clinical status ordinal scale. The Company will now complete site initiation visits and contracts to add additional clinical sites to the study.
“It’s clear from comments of infectious disease experts like Dr. Anthony Fauci and recent news reports on emerging COVID-19 variants that we are not out of the woods yet with the coronavirus, by any stretch of the imagination. Even with vaccines starting to be rolled-out, it is going to be many more months for them to reach the masses and potentially years before vaccines are available worldwide,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “There is now and will be into the foreseeable future a real need for new therapeutics to treat people who contract the infection. We have great hopes Brilacidin will emerge as a novel therapeutic to help fight the global pandemic.”
Sent email IR responded with Auto-Response well at least they are paying for the website still.
ICNM Investor Relations <info@iconmediaholdings.com>
To: XXXXXXXXXXXXXXXXXX
Hello and thank you for contacting Icon Media Holdings, Inc. We have received your email and respond as quickly as we can. Please note that any requests for information that can be deemed as "Inside Information" will not be responded to.
Thank you,
Investor Relations
Icon Media Holdings, Inc.
Forward-Looking Statements & Disclaimers:
The information in this Press Release includes certain "forward-looking" statements within the meaning of the Safe Harbor provisions of Federal Securities Laws, as that term is defined in section 27a of the United States Securities Act of 1933, as amended, and section 21e of the United States Securities Exchange Act of 1934, as amended. Statements in this document, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Investors are cautioned that such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release, and the Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.
Weird I see a PM hit for 50 shares at T-2 but no bid
Strange things happening in OTC lately. Could $ICNM get some love someone is loading.
©2020 Icon Media Holdings, Inc.
Keeping website alive.
http://iconmediaholdings.com/
Trip plays running hard these days. Little DD seems to go a long way lately current or not.
Definitely not!! Probably note if company themselves isn't doing it. Has a bit of unrestricted note holders it seems.
Yes Set your GTC for 0013 I will take them....LOL
Good News Boom.
Foundation Farms Corp. To Shake Up Vertical Farming Industry By Implementing Cavitation Technology Into Its Vertical Farms With Its E-ROOTS Process.
Press Release | 12/16/2020
Foundation Farms Corp. To Shake Up Vertical Farming Industry By Implementing Cavitation Technology Into Its Vertical Farms With Its E-ROOTS Process.
PR Newswire
NEW YORK, Dec. 16, 2020
NEW YORK, Dec. 16, 2020 /PRNewswire/ -- Foundation Farms, Corp., ("Foundation Farms") a subsidiary of GME Innotainment, Inc. ("GMEV") today announced that it has developed its own proprietary process that it is calling its E-ROOTS process which will be incorporated into each vertical farm that is built, owned and operated by the company. This process incorporates patented hydrodynamic and ultrasonic cavitation equipment as the core technology along with air injection to enhance crop production through natural root stimulation techniques.
Cavitation is a natural phenomenon which has numerous examples in nature, the largest of which is the role it plays in the cleanup and health of the world's rivers and oceans. Waterfalls and rapids in fast-moving rivers and crashing waves in oceans and lakes create numerous cavitation events providing re-aeration and cleansing of the water.
Cavitation involves the formation of thousands and even millions of water vapor micro-bubbles in the moving fluid followed by their sudden pressure-induced collapse. The resulting phenomenon is the instantaneous release of tremendous quantities of thermal and mechanical energy. In the technology world, most people are quite familiar with the negative results of unwanted cavitation—the erosion of water pump impellers and boat propellors. Despite many attempts over the years by engineers and scientists to develop technology to harness the positive potential of cavitation, it is only recently that certain individuals and groups have succeeded in developing mechanical equipment that generates controlled cavitation without destroying itself in the process. This new and proven technology is what Foundation Farms will utilize in its process.
From a technology perspective, the E-ROOTS process is relatively simple to install and operate, has a low operating cost and comes with significant benefits:
We believe that the E-ROOTS process will create a supersaturated oxygen condition in the water-based nutrient solution that is fed to the growing plants. Research shows that higher dissolved oxygen levels in the root zone of most crops results in a higher root mass. A plant with more root mass grows healthier and faster. A plant's roots are where it gets the majority of its inputs for growth, including water and nutrients. Healthy roots with a good supply of oxygen have better respiration and are able to selectively absorb more ions in solution, such as vital mineral salts, nitrogen, phosphorus and potassium. Evidence suggests that plant growth increases with super-saturation levels of dissolved oxygen, reducing cropping times and increasing fruiting or flowering yields. We anticipate that the E-ROOTS system will maintain super-saturated dissolved oxygen levels that are much higher than that of the saturated level of dissolved oxygen in clean non-cavitated water.
The E-ROOTS process will provide natural disinfection without the use of chemicals. The energy released during cavitation generates low levels of hydrogen peroxide from water molecules thereby eliminating potential plant disease vectors such as fungi and pathogenic bacteria. This also reduces biofilm formation in pipes and nozzles which tends to consume dissolved oxygen and leads to clogging issues.
We assume that the same cavitation energy that breaks apart water molecules which reform into hydrogen peroxide also breaks apart larger water molecule clusters into smaller clusters that can be more easily absorbed by root cells resulting in more efficient use of water and nutrients while also accelerating plant growth processes.
Ed Kroeker, CEO of Foundation Farms stated, "My life interests, professionally, have revolved around agriculture, food and water. For the past 40 years I have designed numerous water treatment facilities around the world. During the last six years I had the unique privilege of assisting in the commercialization of a recently patented cavitation system. I am excited to be able to bring this knowledge and experience into our vertical farming ventures. I am convinced that the impact of E-ROOTS technology on the profitability of the vertical farming industry will closely parallel the impact of LED lighting technology. LED lighting is focused on optimizing energy transmission to the plant tops and E-ROOTS optimizes energy transmission to the roots."
Yves R. Michel, GMEV CEO commented: "Foundation Farms is establishing new horizons within the rapidly growing vertical farming industry. We are excited about the further developments made by the Company."
$GMEV CDEL buying bid selling ask Hmmmm......I know what's up. I know you do too.
Must be the 15th FINRA short Report due.